But for all of the progress the company has made to that end (below we’ll highlight some of the more implicative and major 2012 milestones), this progress has presented perhaps an under-served challenge for biotechnology, pharmaceutical, and related-medical publicly-traded companies: a barrier to achieving a fundamental understanding of what the company does, and an inability to segregate the science behind the business from the business itself.

Marina Biotech is a case in this point. Here is the company’s short description that accompanies their press:

Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs — in bladder cancer and myotonic dystrophy.

It’s my conjecture that very few retail investors, who happen to stumble across the company’s ticker, save from investors who specifically seek out companies introducing RNA-based therapeutic products or those who possess an extensive background in biological science or technology, will successfully arrive at an even crude interpretation of what this actually says. But then it goes on:

Marina Biotech has entered into an agreement with both Mirna Therapeutics and ProNAi Therapeutics to license Marina Biotech’s SMARTICLES® technology for the delivery of microRNA mimics and DNAi, respectively. In addition, Marina Biotech announced exclusive licensing agreements with Monsanto Company for Marina Biotech’s delivery and chemistry technologies and with Girindus America for the supply of CRN-based oligonucleotides. Marina Biotech recently entered into a non-exclusive agreement with Novartis Institutes for Biomedical Research to license Marina Biotech’s CRN technology for development of nucleic acid-based therapeutics.

The prudent investor will have noticed a few prominent, noteworthy accomplishments on Marina’s behalf: a licensing agreement with Mirna Therapeutics and ProNAi Therapeutics, whom may or may not be related, and three more agreements with Monsanto Company, Girindus America, and the Novartis Institute. These agreements are based at least in some large part on the development of some unique application of DNAi, a nucleic acid-based therapeutic, called SMARTICLES. But this doesn’t tell us much about what that application is or how it works, or just how “big” these agreements are for Marina. So before we dig a little deeper, let’s take an inventory of what we know so far.

Marina Biotech’s big 2012 accomplishments

• The company began trading on the OTC Markets presumably to avoid the cost and hassle of NASDAQ compliance, which likely freed up time and money to focus on the company’s products
• Those products are based on specific, developed, and proprietary therapeutic applications of something called RNAi
• Monsanto Company, the world’s largest seed company and regularly cited as one of the most innovative agricultural producers to ever exist, has entered into an exclusive licensing agreement to deliver some form of the company’s technology, and similar agreements with four other partners, one of which is the research and development arm of Novartis Pharmaceuticals, one of the world’s largest diversified medical companies.

Of course, to understand why any of these agreements, if any of them, are significant, we would need to spend many, many hours reading through each of the company’s intellectual property agreements for each of the partners, to gain a comprehensive understanding from which we can conclude with confidence how much each agreement is for, just what these IP assets are worth, and place an evaluation of just what these arrangements are worth over a short and long-term horizon.

If you would like to begin that process, you could start here with Marina’s 8-K filed on November 14^th, 2012 releasing the terms of the Monsanto agreement.

This is a scope that beyond the main purpose of this article. The purpose of this article is to bring to your attention a company that is generating a lot of news that should be of poignant interest for retail shareholders who are interested in exposing themselves to the biotechnology industry, assuming you’re reading this because you are one of those shareholders, and encourage you to look a little deeper into the research and technology that’s driving this interest from these uniquely diversified partners.

You could start your research by grasping the basic of RNA Inference, or RNAi for short, which is essentially a process whereby the introduction of an enzyme called “Dicer” effectively splits the protein expression that makes up a disease strand – herpes simplex, for example – thus stifling the regeneration of the targeted strand. RNAi was discovered in the early 1990’s and popularized by two genetic scientists who coined the term RNA Inference in a 2008 paper after winning a Nobel Prize in Physiology or Medicine for demonstrating the potency of the RNAi process in laboratory plants.

The effectiveness of RNAi is the foundation on which Marina has developed their licensed processes on, specifically UNA (Unlocked Nucleobase Analogs), siRNA, and CRN. Most recently, Marina announced yesterday that the USPTO has issued United States Patent number 8,314,227 in connection with the use of UNA in a number of RNA-based therapeutics. You can read the full patent application here.

Next, consider these headlines from 2012 and take a read of each one (in order from least to most recent for 2012):

• Marina Biotech Announces Closure of Cambridge Site and Consolidation of R&D Operations in Bothell, WA
• Marina Biotech and ProNAi Therapeutics Announce License Agreement for the Development of DNAi-based Therapeutics
• Marina Biotech, Inc. to Raise $1.2 Million in Registered Direct Offering
• Marina Biotech Regains Intellectual Property Rights to its tkRNAi™ Technology for Agriculture and Veterinary Uses
• Marina Biotech Announces Worldwide Exclusive Licensing Agreement with Monsanto
• Marina Biotech Receives Three Notices of Allowances from the USPTO and an Intent to Grant Notice from the European Patent Office
• Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement for Nucleic Acid Chemistry
• Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement
• Marina Biotech Announces that Licensee ProNAi Therapeutics Reported Phase 1 Study Results using SMARTICLES® Nucleic Acid Delivery Technology

Marina’s audited fiscal year 2011 results

Finally, consider the company’s full 2011 audited financial performance. Marina reduced its outstanding loan obligations by issuing common stock warrants by approximately $1.2 million and slashed its research and development and administrative expenses across the board in an effort to conserve cash and increase liquidity. The company had $2 million in cash at the end of 2011.

Revenue for the year totaled $2.2 million, while the net loss was exacerbated due to an approximate $16 non-cash adjustment to the carrying cost of its intangible assets, an accounting change called an “impairment test” the company opted to implement for the year. Net loss was $29.4 million on 10,551,193 shares outstanding. The public float as of January 2012 is 10,537,184, and there 180 million shares authorized. The company is audited by KPMG, LLP, and independent registered public accounting firm.

During 2012, the company announced they had raised an aggregate total of $2.6 million, the result of a combination of secured loan and public stock offering proceeds and upfront payments in connection with the company’s licensing agreements. Read the full 10-K here.

Shares of Marina have gained nearly 80% over the last 32 days, from a closing price of $0.38 on November 5^th, to yesterday’s close at $0.68. The stock is thinly traded, averaging about 86k shares a day.

The post Marina Biotech (Pinksheets: MRNA) A Biotech in Plain English appeared first on Bullworthy, LLC.

Interested shareholders can access the Bullworthy Issuer Profile for TGWI here (http://bit.ly/WP7tCi). To access the Bullworthy Equity Research Report for TGWI directly, Click Here. Readers are encouraged to join Bullworthy’s Issuer Alerts, an email alert service that pushes analyst coverage, updates, and commentary on covered issuers in real-time to subscribers.

Senior Equity Analyst Tom Copeland of Bullworthy, LLC explores the company’s corporate history, the Oklahoma-based White No. 12-1 oil and saltwater disposal well the company purchased this year, and income projections derived under several variable conditions and P/E valuation models.

The report also explores the growing role of independent U.S. oil and gas producers in the global oil marketplaces, and how domestic demand trends will drive market value growth through 2030.

Disclosure: Bullworthy, LLC, has been compensated two thousand five hundred dollars cash by a third party to prepare, publish, and distribute this report. Bullworthy, LLC maintains that no one other than the certifying analyst has participated in the production of this report. Bullworthy, LLC, including its partners, owners, analysts, or employees, have never, nor will ever, buy or sell shares in any of the stocks or issuers covered in any of the company’s research report or on the website. For full disclosure, please review the Bullworthy Universal Investment Disclosure by clicking here (http://www.bullworthy.com/disclosure).

About Bullworthy, LLC

Bullworthy, LLC is an emerging independent equity research and analyst firm focused solely on micro and small-cap publicly-traded companies. For more information about Bullworthy, LLC please visit www.bullworthy.com.

About Tenguy World International, Inc. (Pinksheets: TGWI)

Tenguy World International, Inc. is a development stage independent oil and gas exploration and drilling company based in Houston, Texas. The company’s shares trade on the OTC Pinksheets (current) market. For more information, please visit www.tenguyworldint.com.

Please direct all media and investor queries to:
Tom Copeland
Senior Equity Analyst, Bullworthy, LLC
(561) 275-1183

The post Bullworthy Announces Equity Research Report: Tenguy World International, Inc. (TGWI) Projecting $0.057 12-Month Price Target appeared first on Bullworthy, LLC.

OPEL Technologies is publicly traded on Canada’s TSX-Venture Exchange and also quoted on the OTC Markets Pinksheets tier as OPELF. The company has a market capitalization of $22 million, with 94 million shares outstanding and a 52-week high and low of $0.19 and $1.82, respectively.

To understand the company’s business, it’s necessary to first understand the assumed need OPEL Technologies fulfills. Optoelectronics (OE) are small defined as small electronic components comprised of two individual and independent pieces of equipment that when combined serve specific purposes in devices: electronic transmitters and optics (either fiber or integrated). The photo below puts this combination into visual context (the photo is attributed to Mechanical Engineering Blog).

Once combined, OEs can be used in a multitude of optics-based technologies that include, but aren’t limited to, solar panels, infrared technologies, telecommunications, mobile devices, medical instruments, and other applications that require the detection and manipulation of a light source (“light source” in electronic engineering terms is a very loose term that can be applied in many contexts, for example as gamma rays or X-rays, LEDs, etc.)

OPEL Technologies owns a portfolio of 37 patents, with an additional 13 pending, that protect the company’s proprietary next-generation optoelectronics devices called Planar Optoelectronic Technology (POET). POET essentially combines the electronic transmitter and the optics components onto one single chip, as opposed to a traditional conduit that relies on the independent cooperation of the two components.

The company has contended that the result is:

• A drastic reduction in size of the components
• A simplified manufacturing process
• Reduced power consumption
• Processing speed advantage

In the company’s driver seat is Dr. Geoffrey W. Taylor, chief scientist at OPEL Technologies. Dr. Taylor holds a Bachelor of Science in Electrical Engineering from Queens University, and received both his Master’s and Ph.D. in the same field from the University of Toronto. Prior to his development of POET, which he’s been cultivating over the last decade, Dr. Taylor was a 14-year veteran of AT&T Labs. His work and studies of the subject have been published in a dozen peer review science journals, including his most recent piece entitled Performance of Subsamples Optical Links on May 1^st, 2012 in the Journal of Lightwave Technology.

The company is still in the research and development phase, conducting its continued research out of a lab at the University of Connecticut, and for 2012 will take some write-downs on OPEL Solar, a business division that has been expunged and discontinued due to its demanding capital resource requirements and slowing sales. The company could raise more than $1.5 million off the sale the OPEL Solar assets, according to the most recent 10Q filed on November 19^th, 2012.

The company is currently receiving financial support from government contracts, including a grant provided by the American Reinvestment and Recovery Act of 2009. The company is also working with BAE Systems to independently validate OPEL’s technology and substantiate a proof of concept.

The company reports $3.5 million in assets for the first nine months of 2012 and $1.2 million in liabilities. OPEL is flush with cash, holding $1.8 million on the books, but reported just $112,070 in revenues for all of 2012. This analyst found reason to believe in OPEL’s latest filling that the company may be gearing up to raise additional cash to sustain operations and research associated with the commercialization schedule, which the company has identified will begin to commence in the first quarter of next year.

Since 2010, the company has successfully raised about $2.75 million from various entities and supporters, including the U.S. Air Force, NASA, BAE Systems, and the U.S. Navy.

By demonstrating the company can raise substantial capital from these dedicated partners indicates that these supporters are likely expecting to one day become customers.

Sources: Mechanical Engineering Blog, OPEL 2012 Investor’s Presentation

The post OPEL Technologies Inc (OPL.V) Undiscovered TSXV Technology Stock appeared first on Bullworthy, LLC.

Interested shareholders can access the Bullworthy Issuer Profile for AZFL here. To access the Bullworthy Equity Research Report for AZFL directly, click here. Readers are encouraged to join Bullworthy’s Issuer Alerts, an email alert service that pushes analyst coverage, updates, and commentary on covered issuers in real-time to subscribers.

Senior Equity Analyst Tom Copeland of Bullworthy, LLC delineates in fine detail how a convergence of a unique cause-driven business model, a diverse line of timber operations, and the growing influence of domestic and global demand for hardwood could propel the company to record as much as USD $48 million by 2017. Mr. Copeland interviewed Michael Ibar, Amazonas Florestal’s CEO, in preparation for this coverage.

The report covers the history of the company and the executive team, a robust market analysis, and multiple financial performance projections for revenue, earnings, and price targets.

Disclosure: Bullworthy, LLC, has been compensated two thousand two hundred dollars cash by a third party to prepare, publish, and distribute this report. Bullworthy, LLC maintains that no one other than the certifying analyst has participated in the production of this report. Bullworthy, LLC, including its partners, owners, analysts, or employees, have never, nor will ever, buy or sell shares in any of the stocks or issuers covered in any of the company’s research report or on the website. For full disclosure, please review the Bullworthy Universal Investment Disclosure by clicking here.

About Bullworthy, LLC
Bullworthy, LLC is an emerging independent equity research and analyst firm focused solely on micro and small-cap publicly-traded companies. For more information about Bullworthy, LLC please visit www.bullworthy.com.

About Amazonas Florestal, Ltd. (Pinksheets: AZFL)
Amazonas Florestal, Ltd.is a diversified forest management company generating profit through innovative, sustainable forest management in Amazonas, Brazil. For more information, please visit www.amazonasf.com.

Please direct all media and investor queries to:
Tom Copeland
Senior Equity Analyst, Bullworthy, LLC
(561) 275-1183

The post Bullworthy, LLC Releases Bullworthy Equity Research Report – Amazonas, Florestal, Ltd. (Pinksheets: AZFL) Projecting 12-Month $0.27 Price Target appeared first on Bullworthy, LLC.

In preparation for the 2013 timber harvesting season,  which begins in Amazonas, Brazil on May 1st of every and lasts through December 31st, the company has been quietly working on acquiring the proper SFM plans and licensing it needs to begin harvesting operations. The company acquired two properties, Dos Ramos I and Dos Ramos II, both with active SFM permits that allow an extraction yield of up to 14,000 cubic meters.

And for the Fazenda Jatuarana property, a swath of virgin Amazon forest the company purchased in 2010 that’s expected to yield approximately 1.5 million cubic meters, the company is already in the process of applying for SFM licensure to extract the first 40,000 cubic meters during the 2013. If granted as management expects it will be, AFL would be legally permitted to extract a total of 54,000 cubic meters of timber next year.

That means management should be hard at work now to secure partners to facilitate each node in the supply chain. In a company disclosure filed earlier this month, management released the names of the companies they have begun negotiations with. We’ve re-produced that information into a simple chart:

The chart, on the surface, tells us a few things:

• The company’s AFL is considering as potential supply chain partners
• That the “production” node partner will depend directly on the order being fulfilled (for example, if AFL is milling timber for use in hardwood patio decks, the partner would presumably be a provider that specialized in milling the raw timber into hardwood patio decks panels)
• The the company will be exporting to a global marketplace, but will also be selling to the emerging Brazilian market as well

There are less extrinsic implications for this chart as well, however. What this supply chain modeling tells us is that the company is planning on being involved in every step of the timber operation, from extraction to final delivery of finished product. It’s that kind of quality control management that shareholders and potential shareholders, as well as customers, vendors, and the state’s regulatory bodies, appreciate from a SFM timber producer.

The post Research Report Feature: Amazonas Florestal, Ltd (AZFL) Timber Supply Chain Management appeared first on Bullworthy, LLC.

Genius Brand’s CEO Klaus Moeller expresses pride in the Baby Genius’® success in penetrating the digital and online component of a child’s learning experience that parents are growing more comfortable with and accustomed to. He puts it this way:

“It’s wonderful to share our videos with young children and their families through all forms of online and social media including our YouTube channel…Millions of views on YouTube also promote our Baby Genius® branded products including our new line of musical and early learning toys which are now available at Babies ‘R’ Us stores nationwide.”

The press, in this analyst’s opinion, affirms a few key points we made in our research report released in July 2012 on GNUS:

• The company is re-focusing a strategic shift away from growing the brand by unilaterally making and selling tangible CDs, DVDs and toys, and instead is opting to leverage the cheap and scalable means of capturing brand loyalty through free digital media to support the purchase of physical products both online and off.
• If that is true, then the fact that the company is growing its digital footprint is evidence of progress being made towards that new focus is also true.
• By focusing on cheap digital content production and proliferation (including the likes of Baby Genius® branded YouTube videos, free smartphone apps, and iTunes music downloads, all of which the company has released) and building a bond with parents, the company can grow the brand without having to focus on manufacturing Baby Genius® toys and products, instead licensing them out to established toy manufacturers like JAKKS Pacific.

In other words, the company used to juggle branding, production of the products, marketing, and operations of the Baby Genius® line of toys, music, and DVDs. The company was limited by how much time it could allot to specific efforts that could or would help Baby Genius® product sales grow.

By retaining the same profits margins by outsourcing the production and manufacturing of goods through the implementation of comprehensive and flexible licensing program to partners like JAKKS, the company frees up resources to focus on growing the brand with existing customers and on acquiring new ones.

Of course the assumption here is that growing brand recognition, awareness, and loyalty among the company’s target consumers, which for purposes of this analysis includes children and their parents, will result in increased sales of the company’s branded products both online and in stores.

That assumption remains to be validated for GNUS. But if the likes of Walk Disney and other companies that pioneered the business of licensing children’s brands is any indication of viability in this business model, Genius Brands could be in the midst of developing a winning formula for Baby Genius®.

The post Genius Brands International (GNUS) Leveraging Digital Footprint To Drive Brand Recognition appeared first on Bullworthy, LLC.

The latest Form 4 (Statement of Changes in Beneficial Ownership), filed today, shows Dr. Frost owning more than 118.4mm shares, representing nearly 40% of the company’s outstanding shares, at prices commensurate with today’s trading levels (yesterday, on November 5^th, 2012, more than 60,000 shares were purchased for a price that ranged from $4.21 to $4.29 a share).

Dr. Phillip Frost buys over 100mm shares using investment trust vehicles

The securities are held by Frost Gamma Investments Trust, owned by Frost Gamma L.P., listing Dr. Frost as the trustee. He is also only one of two limited partners of Frost Gamma L.P., with Frost Gamma Inc. being the other. The sole owner of Frost Gamma Inc. is Frost-Nevada Corporation, which is owned solely by none other than Dr. Phillip Frost.

Don’t let the tangled web confuse you. The complicated ownership structures of these entities are designed, in my analysis, for no reason other than investment tax and estate tax efficiency purposes. While it is not technically Dr. Phillip Frost who is on the stock certificates at the transfer agent, he is the only actual living, breathing human that benefits from an appreciation in the price of his mounds of stock. He was even purchasing stock through 2009, when the share price embarked on a remarkable climb from less than a dollar to a high of around $5.50 a share last year.

Opko Health is an emerging multi-national pharmaceutical and diagnostics company that focuses on bringing its portfolio of proprietary diagnostic technologies to market. From OPK’s latest quarterly report for the period ending on June 30^th, 2012, filed in August:

We are developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, point-of-care tests, and proprietary pharmaceuticals and vaccines. We plan to commercialize these solutions on a global basis in large and high growth markets, including emerging markets. We have already established emerging markets pharmaceutical platforms in Chile and Mexico, which are generating revenue and which we expect to generate positive cash flow and facilitate future market entry for our products currently in development. We also operate a specialty active pharmaceutical ingredients (“APIs”) manufacturer in Israel, which is currently generating revenue and positive cash flow, and which we expect to play a valuable role in the development of our pipeline of peptoids and other molecules for our proprietary molecular diagnostic and therapeutic products. We continue to actively explore opportunities to acquire complementary pharmaceuticals, compounds, technologies, and businesses.

We are incorporated in Delaware and our principal executive offices are located in leased offices in Miami, Florida. We lease office and lab space in Jupiter and Miramar, Florida, which is where our molecular diagnostics research and development and oligonucleotide research and development operations are based, respectively. We lease office, manufacturing, research and development and warehouse space in Woburn, Massachusetts for our point-of-care diagnostics business and in Nesher, Israel for our API business. Our Chilean operations are located in leased offices and a leased warehouse facility in Santiago, Chile, and we own an office and manufacturing facility, and lease a warehouse facility in Guadalajara, Mexico.

Financial highlights of the most recent OPK 10Q report:

• Quarter-over-quarter revenue growth of 16%; fourth straight quarter of growth
• Acquisitions: Farmadiet Group Holdings, a European pharmaceutical manufacturer and marketer; and ALS  Distribution Limitada, a privately-held Chilean pharmaceutical company
• Announced collaboration with LapCorp, an S&P 500 healthcare company, to develop new diagnostic technologies for Alzheimer’s patients and concrete plans for commercialization
• Continued research and development costs related to the company’s molecular diagnostics line of products, produced by OPKO Diagnostics, Inc., and wholly-owned subsidiary, and CURNA, Inc.

The company also reported cash and cash equivalents of $55.3 million, or about $.18 per share. That represents just a small part of the bigger picture of Opko’s strong fiscal position. The company also has access to more than $18 million through various lines of available credit. The company only owes $14.6 in short-term and current liabilities.

The balance sheet reports $230.4mm in total assets, $54.2mm in total liabilities, and $151.5mm in shareholder equity. That represents a debt-to-equity ratio of just 36% and a quick ratio of 2.91. The significance of these numbers becomes apparent when you consider that the company’s peers in the medical equipment industry typically have much more debt and much less cash as a quick comparison to cash and current assets.

The company isn’t shy in using in using its stockpile of cash, in combination with stock, to make bold acquisitions. In October, the company purchased a 100% interest in Prost-Data, Inc., doing business as OURLab by merging it with the OPKO Laboratories, Inc. subsidiary. The final purchase price would be $9.4mm in cash and $30.6 million in stock. The press release states:

OURLab provides OPKO with a commercial platform to support the near-term U.S. commercial launch of its novel panel of kallikrein biomarkers and associated algorithm (4Kscore™) for the detection of prostate cancer. The OPKO 4Kscore™ is the result of a decade of research by scientists in Europe and the U.S. and has been demonstrated in more than 10,000 patients to predict the probability of positive biopsies in men suspected of having prostate cancer. Extensive studies have shown that the use of the 4Kscore™ may reduce the number of unnecessary prostate biopsies by 50% or more, avoiding the frequent complications of pain, bleeding, and infection, which sometimes require hospitalization. The data indicate that even with the significant reduction in the number of biopsies performed, the probability of delaying diagnosis of a high grade cancer was only 0.6%. Men whose 4Kscore™ is low enough to not lead to biopsies would be followed with active surveillance by the urologist.

With 132.41mm shares in the float, about 300mm issued and outstanding, and 53% of the shares owned by insiders, Opko and its directors are obviously not shy in regards to their confidence in the company. Accordingly, analysts have taken notice.

On October 21^st, 2012, just days after the OURLab deal was finalized, analysts from Barrington Research initiated coverage on the stock with an OUTPERFORM rating and a price target of $7.50. The stock is down 18% over the last 12 months and down 5% from a 1 month high of $4.69 on heavier than average volume. Analysts issuing the coverage will likely suggest the stock has been oversold for 2012.

As a trader, it’s your job to take this information and make a decision. With Opko, you’ve got at least four years of consistent and aggressive open-market stock accumulation by the Chairman and CEO through a grapevine of personal investment and trust entities; an industry that is growing at break-neck speeds; strong capital and liquidity resources to carry R&D well into the decade; cash and stock that’s available for swift and strategic acquisitions, and a proven willingness to do so; and an analyst that for the first time is initiating coverage on the company.

Make a move, or try to find a better one.

Tom Copeland
Senior Equity Analyst, Bullworthy, LLC.

Resources: Opko Health IR website (http://investor.opko.com/index.cfm); Opko shareholder presentation at Jefferies 2012 Global Healthcare Conference (http://bit.ly/TuRbt9). Charts courtesy of Yahoo! Finance.

The post The Holy Grail of Insider Buying Demonstrated by CEO of Opko Health, Inc (NYSE: OPK) appeared first on Bullworthy, LLC.

WEST PALM BEACH, FL –(Marketwire – 10/31/2012)- Bullworthy, LLC, an emerging independent equity research firm specializing in high-quality analyst coverage for micro and small-cap stocks, announced the release of the Bullworthy Equity Research Report – Gunther Grant, Inc. (Pinksheets: GNGR) with a BUY rating and a five-year price target range of $0.013 to $4.87.

Interested shareholders and traders can access the Bullworthy Issuer Profile for GNGR here. To access the Bullworthy Equity Research Report for GNGR directly, click here. Readers are encouraged to join Bullworthy’s Issuer Alerts, an opt-in email listserve that pushes analyst coverage, updates, and commentary on covered issuers in real-time to subscribers.

The report describes in detail how the company’s shift in focus to large commercial wholesale production coupled with a growing demand for chocolate offers significant opportunities for Gunther Grant. The report is certified by Tom Copeland, head analyst at Bullworhy, LLC, who interviewed Gunther Grant CEO Grant Newsteder in preparation and fact-gathering for this coverage.

The report covers the operational history of the company and the founder, robust market and opportunity analyst, and a case for projected financial performance and stock price targets through fiscal year 2016.

Per the coverage agreement, Bullworthy, LLC, has been compensated two thousand one hundred and ninety dollars cash by Microcap Innovations, LLC to prepare, publish, and distribute this report. Bullworthy, LLC maintains that no one other than the employed analysts at Bullworthy, LLC has participated in the preparation or review of this report. Bullworthy, LLC, including its partners, owners, analysts, or employees, have never, nor will ever, own shares in any of the stocks or issuers covered in any of the company’s research report or on the website. For full disclosure, please review the Bullworthy Universal Investment Disclosure by clicking here.

About Bullworthy, LLC

Bullworthy, LLC is an emerging independent equity research and analyst firm focused solely on micro and small-cap publicly-traded companies. For more information about Bullworthy, LLC please visit www.bullworthy.com.

About Gunther Grant, Inc. (Pinksheets: GNGR)

Gunther Grant, Inc. owns controlling interest and manages various companies in the confections industry that specialize in chocolate production, confection technology, mold production, and specialty advertising. For more information, please visit www.gunthergrant.com.

The post Bullworthy, LLC Releases Bullworthy Equity Research Report – Gunther Grant, Inc. (Pinksheets: GNGR) Projecting $1.25 Price Target appeared first on Bullworthy, LLC.

WEST PALM BEACH, FL –(Marketwire – 10/01/2012)- Bullworthy, LLC, an emerging independent equity research firm specializing in high-quality analyst coverage on micro and small-cap stocks, has initiated coverage on Oriens Travel & Hotel Management Corp with a BUY rating and a five year price target range of $0.10-$1.26.

Interested shareholders and traders can access the Bullworthy Issuer Profile for OTHM by clicking here. To access the Bullworthy Equity Research Report for Oriens directly, click here. Readers are encouraged to join Bullworthy’s Issuer Alerts, an opt-in email listserve that pushes analyst coverage, updates, and commentary on covered issuers in real-time to subscribers.

The report provides buy and sell side market analysts, retail, and institutional investors with a complete, objective, and professional analysis of the proprietary assets that support Oriens business model, the industry and market opportunity analysts believe the company fulfills, reinforced by conservative revenue, earnings, and stock price projection through 2016.

Per the coverage agreement, Bullworthy, LLC, has been compensated one thousand five hundred and eighty five dollars cash by MicroCap Innovations, LLC to prepare, publish, and distribute the research report on the issuer being covered. Bullworthy, LLC analysts maintain in the report’s disclosure that no one other than the employed analysts at Bullworthy, LLC has written, edited, reviewed, approved, or otherwise influenced the opinions presented in the report, not limited to the projected financial models, price targets, or investment recommendations. The company, including its partners, owners, analysts, or employees, have never, nor will ever, own shares in any of the stocks or issuers covered in any of the company’s research reports or on the website. For full disclosure, please review the Bullworthy Universal Investment Disclosure by clicking here.

About Bullworthy, LLC

Bullworthy, LLC is an emerging independent equity research and analyst firm focused solely on micro and small-cap publicly-traded companies. The company is headquartered in West Palm Beach, Florida, with a satellite office in Denver, Colorado. For more information about Bullworthy, LLC and its team of analysts, please visit www.bullworthy.com.

About Oriens Travel & Hotel Management Corp (Pinksheets: OTHM)

Oriens Travel & Hotel Management Corp engages in the operation of hotels and resorts primarily in the United States and Central America under the Hotel PURE brand. The company also operates Friendly Reservations Online, a proprietary and sophisticated online booking system designed to execute reservations capture through Hotel PURE consumer facing websites, as well as individual hotel websites operated by Oriens on behalf of hotels branded under the Hotel PURE brand. Oriens is based in Las Vegas, Nevada. For more information, please visit www.orienscorp.com.

The post Bullworthy, LLC Initiates Coverage on Oriens Travel & Hotel Management Corp (Pinksheets: OTHM) With Detailed Equity Research Report and $0.10 Price Target appeared first on Bullworthy, LLC.

It’s the opinion of Bullworthy analysts that management, headed by CEO Ken Chua, considers transparency and reporting to be an important aspect of building shareholder confidence and have therefore opted to make important and material company information publicly available in compliance with the Alternative Reporting Standard commonly invoked by OTC Pink Limited Information® tier companies.

A micro-cap company of Orien’s size may wish to bolster complaince and transparency for shareholder and regulators for several reasons. Among the most likely in this case could be the beginning of a commitment to regular, standing reporting.

In the report, which can be accessed from the OTHM profile found on the OTCmarkets.com website, the company records total assets of $3.73 million versus total liabilities of $2.62 million.

The post Oriens Travel & Hotel Management Corp (OTCpink: OTHM) Issues Quarterly Report appeared first on Bullworthy, LLC.

This press release is sourced to Oriens Travel & Hotel Management Corp, released through PRNewswire, and has only been slightly altered (only in the HTML formatting) by Bullworthy, LLC.

LAS VEGAS, Sept. 5, 2012 /PRNewswire via COMTEX/ — Oriens Travel & Hotel Management Corp. (Pinksheets: OTHM), the Next Generation International Hotel Brand Operator, operating its Hotel PURE brand, announced the completion of upgrades to its Online Booking System. “Following the completion of our Online Booking System just a year ago, our platform has undergone rigorous beta testing by numerous hotels using our software,” stated Ken Chua, President of Oriens. “The results have been quite positive, and the current upgrades we’re implementing will only make the booking progress more seamless and easier.”

This same system recently received a facelift integrating various upgrades including payment gateways for processing credit cards (Visa, MasterCard, Amex), PayPal payment solutions, Google Payment Solution, 128bit security encryption (ensuring all data collected on the website is securely transmitted to its server), and a more user-friendly backend platform being used by hotel revenue managers on a daily basis. Oriens Booking System is now capable of handling over a thousand reservations per minute, simultaneously powering an unlimited number of individual hotel websites as well as the company’s corporate website ( www.HotelPURE.com ). In addition, a dynamic mobile App is being integrated into the system, since, according to research, 52% of consumers will be accessing the web through some form of mobile devices by 2015. A Facebook App is also being coded into the system to ensure connectivity is achieved for marketing and/or room reservation execution.

The Extranet, or Backend of the system, has also received a complete facelift. The newest version will have a similar look and feel to Expedia.com, Travelocity.com and Orbitz.com; thus reducing the learning curve by those hoteliers using our Booking System.

“Going forward, our Booking System will consistently receive upgrades by our IT department to stay ahead in an industry where a wealth of innovative technology concepts are being introduced into the travel sector on a regular basis,” concluded Chua.

About Oriens Travel & Hotel Management Corp
Oriens Travel & Hotel Management Corp. (Pinksheets: OTHM) (www.orienscorp.com) engages in the operation of hotels and resorts primarily in the United States and Central America under the Hotel PURE brand. The company also operates Friendly Reservations Online, a proprietary and sophisticated online booking system designed to execute reservations capture through Hotel PURE consumer facing websites, as well as individual hotel websites operated by Oriens on behalf of hotels branded under the Hotel PURE brand. Oriens is based in Las Vegas, Nevada.

Safe Harbor Statements in this news release that are not historical facts, including statements about plans and expectations regarding products and opportunities, demand and acceptance of new or existing products, capital resources and future financial results are forward-looking. Forward-looking statements involve risks and uncertainties which may cause the Company’s actual results in future periods to differ materially from those expressed. These uncertainties and risks include changing consumer preferences, lack of success of new products, loss of the Company’s customers, competition and other factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

The post Oriens/Hotel PURE Completes Upgrades on Its Proprietary Online Hotel Booking System appeared first on Bullworthy, LLC.

Driving the bids today was a SEC schedule 13D filing by Greenlight Capital LLC, an institutional arm of hedge fund manager David Einhorn, notifying the public that he, along with six other funds he controls through various entities, purchased an additional 69,000 shares on the open market, upping his total stake in the company to about 36%, according to the filing. [source]

A short squeeze could have also contributed in some ways to the massive stock price swing today. As of August 15^th, 2012, approximately 8.6% of BioFuel’s float was being shorted. [source]

Could analyst have seen the BIOF jump coming?

Einhorn, who sits on the company’s board, and other capitalist and insiders have been buying up BioFuel’s shares and converting options aggressively since at least November of 2011. According to the company’s latest 10K filed back in March for fiscal year ending December 31^st, 2011, there were 1.83 million stock options outstanding at an average exercise price of $3.22 a share.

A wave of change of ownership forms came in this summer, by Scott Pearce, president and CEO; Daniel Loeb, head of hedge fund Third Point, LLC and today a 19% beneficial owner; and Einhorn’s Greenlight vehicles.

While the company reported the second consecutive quarterly loss attributable mostly to higher prices for corn and other central production costs, Einhorn and insiders have quietly been acquiring shares both on the open market and through exercised options.

Insider acquisitions have traditionally signaled to the market that management views their company’s shares as being undervalued. But the case of BioFuel Energy is unique in that a handful of various institutional investment vehicles one of the company’s Board of Directors controls is securing significant equity positions in the company.

The insider’s motivations are unclear. Perhaps they feel the company is a prime take-over target going into fiscal year 2013. Or maybe this is a long-term move.

One thing is for sure: the micro-cap alternative energy producer from Colorado just boosted it’s market cap by about 30% in one trading session following today’s close.

Photo Attribute: bfenergy.com

The post BioFuel Energy Corp (NASDAQ: BIOF) Behind the Scenes of the Einhorn Investment appeared first on Bullworthy, LLC.

Bullworthy Analyst are releasing this morning’s Issuer Alert for Genius Brands International ($GNUS) following the company’s press this morning announcing a licensing deal with a major toy puzzle manufacturer.

Genius Brands International ($GNUS) has granted a three-year licensing agreement to Karmin International, one of the world’s largest toy puzzle manufacturer, the company announced today.

The agreement allows Karmin to design, produce and distribute the company’s branded Baby Genius®-themed toy puzzles for preschool children. The first wave of products will be introduced at the annual Fall Toy Preview 2012, held in Dallas, Texas, during the week of October 2^nd through the 4^th [source].

The Fall Toy Preview is one of the toy industry’s biggest “by invitation only” events hosted by the Toy Industry Association. The conference brings together toy manufacturers and mass market retailers and buyers, giving companies like Karmin the opportunity to showcase their product lines for sale during the fourth quarter of the following year.

Karmin expects to produce an extended line of product categories to appeal to a variety of children’s tastes, including dry erase puzzles, two-sized puzzles, book and puzzle combos, multi-pack puzzles, floor puzzles, and musical puzzles.

Bullworthy analyst opinion

In our Bullworthy Equity Research Report, we postulated after thoroughly examining Genius Brand’s earnings going back to 2006 when the current management team came into place, that the company has been preparing itself to focus the entirety of its strategic operation on licensing the low-margin physical production of toys featuring its proprietary children’s “edu-tainment” brand, Baby Genius®, to major toy manufacturers while keeping the high-margin business of digital content delivery in-house.

Management has been divesting its inventory of the physical Baby Genius® brand CDs and DVDs on deal-a-day websites since 2011, most notably on Groupon, from which, according to our analysis, the company has recorded at least $1.5 million in sales to date. Since 2011, the company began securing licensing and promotional commitments from major distributors like JAKKS Pacific, Sunscape Eyeware, Nokia, and Wendy’s. For more information on these developments, please see the Bullworthy Equity Research Report on GNUS.

The agreement announced this morning giving Karmin International the right to produce and distribute Baby Genius® branded puzzles not only further reinforces this opinion, but also serves as a testament to the goodwill, branding power, and influence of Baby Genius® today and going forward.

This shift in strategic focus and the progress management has made towards fulfilling it will translate into growing sales and profitability for Genius Brands for two reasons, in our opinion.

First, licensing is a high-margin business. Licensing and royalty revenue for Genius Brands in 2011 was $1,032,469, attributable to an agreement with Battat, a toy manufacturer, before the agreement with JAKKS Pacific was announced. Genius Brands expects JAKKS will have produced Baby Genius® brand toys per the agreement in time for the 2012 holiday shopping season.

We pegged forward quarterly revenue projections for licensing and royalty revenue on the peak quarterly performance for the Genius/Battat deal at approximately $400,000. Using that figure, our analysts project licensing and royalty revenue will total at least $2.4 million for 2012 based on historical sales trend data obtained through SEC filings for Genius Brands. That projection was of course made prior to today’s announcement.

The company reported cost of sales at $3.6 million on total sales of $6.0 million during fiscal 2011, representing gross margins of 60%. This was during a year in which total licensing and royalties contributed only about 11% to the top line revenue. We believe that during 2013, licensing and royalty revenue will increase to $2.4 million, or about 28% of projected revenue of $8.3 million, based on our conservative income projection modeling.[source]

Second, the jigsaw puzzle industry continues to grow despite the appeal and subsequent increase over the last few years of digital entertainment media consumption among children. We found a press release from 2011 sourced to Jigsaw Puzzle Outlet, an e-commerce puzzle retailer based out of England. The tagline reads: “Hard-pressed to compete against computer games and technology-driven entertainment options, an industry leader in the jigsaw puzzle market says the old-fashioned pastime has remained popular over the years, evidenced by his company’s noteworthy 25 percent growth in 2010.”[source]

The founder of the company, Michael Carter, who has more than 40 years’ experience in children’s toy retailing, explained that he’s on the verge of hiring more staff to keep up with demand. The website offers hundreds of jigsaw puzzles that span categories targeted at children, families, and hobbyists. The children’s section features puzzles from licensed brands including Thomas & Friends, Toy Story, Barbie and Disney.

Analyst conclusion

Genius Brands has partnered with a worldwide toy manufacturer to license and produce a line of Baby Genius®-branded puzzles for distribution by major mass market toy retailers. We believe the agreement fits cozily into the company’s revamped strategic focus, which seems to be shifting from manufacturing physical toys, CDs and DVDs to selling high-margin licensing rights to companies that have a global footprint and recognition in their industries.

The post Bullworthy Analyst Comment: GNUS Grants License to Karmin appeared first on Bullworthy, LLC.

Compared with second quarter earnings from a year earlier, Concord’s total net revenues grew to (all figures converted to USD from RMB) $21.5 million, an increase of 10.2%. Net income was reported as $6 million, a 2.3% increase from last year’s second quarter.

The company also expanded its footprint to total 133 centers in 52 cities across 24 Chinese provinces. Of particular interest, Bullworthy analyst note is that the company reported having secured 36 new centers slated for development as of June 30, 2012.

By way of simple surface calculations, with net income contributing $6 million to shareholders from 133 operational locations, adding 36 more in the next year could boost net income approximately $1.6 million to $7.5 million, a 27% increase. Quarterly earnings growth year-over-year has historically been 3.6%.

The company is trading higher today by more than 17% on volume of 80k shares, a little more than the 3-month average of 60k, at $3.63 a share. Net income per basic and diluted ADR share was reported as $0.13.

Why Concord Medical’s second quarter earnings matter – returning to profitability

That’s the second straight quarter of bottom-line profits following a year of losses in 2011, as Concord recorded non-GAAP earnings per share of $0.085 in the first quarter 2012. Assume a two-quarter moving average for the full year the company could record $0.43 in basic and diluted EPS for 2012.

That would put the company trading at a price to earnings (P/E ratio) of just 8.8. Compare that the NYSE Composite Index Fund from iShares, which Bullworthy analysts believe to be a good benchmark, of 18.27.

With a relatively low float (16 million shares to 46 million outstanding) and the relatively low volume action for such a massive price swing, we believe the activity today is being fulfilled chiefly on the ask side of the transactions – a bullish indicator of long-term confidence by investors in the stock.

Image Attribute: cmsholdings.com, yahoofinance.com

The post Concord Medical Services Holdings Limited (NYSE: CCM) Solid Earnings, Jumps 17% on Low Volume appeared first on Bullworthy, LLC.

Founder and Chairman J.D. Nichols in partnership with NTS’s CEO Brian Lavin made the offer on August 31^st, 2012 to the company’s board of directors. The proposal is an offer to purchase all of the company’s public limited partnership interests for $5.25 per share in cash.

There are approximately 4.23 million shares in the float with just over 11 million issued and outstanding. Insiders already own over 60% of the company’s public interests. The proposal will not affect the company’s debt structure or the day-to-day operations of the real estate investment trust.

The board of directors said in an SEC filing last Friday they’ve appointed independent directors Mark Anderson, John P. Daly, and John S. Lenihan to a special committee tasked with reviewing and considering the proposal. The board insists no decisions have been made regarding the proposal.

Of special interest regarding the NTS private proposal

• J.D. Nichols, the company’s founder and chairman, and a beneficiary to the proposal, has been purchasing NLP shares in the open market through automatic purchase orders since at least October of 2010. The stock traded as low as $2.95 one year ago this week, triggering orders; Nichols has purchased shares at prices as high as $3.56 a share as recently as February 1^st, 2012.
• The REIT yields a 6% dividend rate, or $.20 a year.
• Rosen Law Firm of New York issued a press release this morning inviting current shareholders of NTS to join in an investigation of the proposed transaction. The firm cites a possible breach of fiduciary duty to shareholders among the company’s board for failing to adequately shop the company before entering into the transaction with Nichols and Lavin, although the board has denied they’ve made a decision.

Photo attributes: ntsdevelopment.com, merchantcircle.com

The post NTS Realty Holdings L.P. (NLP) Going Private Offer of $5.25 per Share appeared first on Bullworthy, LLC.